NCT04354545

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 75 (estimated)
• Sponsor: University of California, Los Angeles · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.

Detailed description

To assess glaucoma patients' response to treatment with Xiidra (Lifitegrast ophthalmic solution) 5% for ocular surface discomfort caused, in part, by topical glaucoma antihypertensive medications.

Conditions

• Glaucoma
• Ocular Surface Disease

Interventions

Type	Name	Description
DRUG	Xiidra (Lifitegrast ophthalmic solution) 5%	FDA approved lifitegrast opthalmic solution eye drop

Timeline

• Start date: 2021-04-01
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2020-04-21
• Last updated: 2026-03-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study